 |
|
|
| |
No DDI Between Bemnifosbuvir/Ruzasvir and
Bictegravir/Emtricitabine/Tenofovir Alafenamide
|
| |
| |
EASL 2025 May 7-10 Amsterdam
Xiao-Jian Zhou,1 Gaetano Morelli,2 Maureen Montrond,1 Shannan Lynch,1 Keith Pietropaolo,1 Bruce Belanger,1 Maria Arantxa Horga,1
and Janet Hammond1
1. Atea Pharmaceuticals, Inc., Boston, USA; 2. Altasciences, Montreal, Canada.
|
| |
|
|
|
|
|
